TORONTO, Aug. 29, 2016 -- Three leading Canadian patient advocacy groups, along with 14 signatories, today presented to the federal government's Task Force on the Legalization and Regulation of Marijuana a brief highlighting the currently unmet needs of medical cannabis patients and how those needs should be addressed as part of the government's commitment to legalize cannabis for personal use.
The brief makes specific recommendations under three broad categories: accessibility, affordability and research. It was prepared and presented by The Arthritis Society, Canadians for Fair Access to Medical Marijuana and the Canadian AIDS Society and built on extensive collaboration between patients, the scientific and medical communities, and medical cannabis experts. The submission is also supported by a broad cross-section of stakeholder signatories.
The groups make seven specific recommendations under the three broad themes:
ACCESSIBILITY
1. Patients must have access to a supply of medical cannabis in all its forms and potencies that is regulated for safety, potency and quality.
2. Patients must have access to a reliable supply of medical cannabis through a variety of distribution options.
3. Patients must be informed about how to access medical cannabis as well as safe and effective use of different forms of medical cannabis (e.g., concentrates, dried flowers, edibles, etc.).
AFFORDABILITY
4. Medical cannabis is a medical necessity and its cost should not be subject to GST, HST or provincial sales tax.
5. The regulatory approach to medical cannabis must enable health insurance plans, both public and private, to be able to reimburse for medical cannabis as they do now for prescription drugs.
SUPPORTED BY RESEARCH
6. The federal government must actively expand the evidence base on the medical use of cannabis through enhanced support and promotion of medical cannabis research.
7. The federal government must use additional policy levers at its disposal to help support and promote research into medical cannabis.
"We are pleased the federal government is examining its position on all uses of cannabis but it is vital that those who use it for medical purposes have a regulatory, pricing and taxation system similar to that for prescription drugs," said Janet Yale, President and CEO of The Arthritis Society. "We know that medical cannabis is an effective therapy for thousands of Canadians with arthritis pain but we need to substantially expand the evidence base through enhanced investment in research."
"The government must ensure that those who need cannabis for medical purposes are prioritized as we move into a legal regulatory system for recreational cannabis," said Jonathan Zaid, Founder and Executive Director of Canadians for Fair Access to Medical Marijuana. "Legal access to cannabis for legitimate medical purposes must be treated differently, with appropriate laws and regulations to enhance access, increase affordability and bolster research."
"In the new regulated system, we must ensure that Canadians living with HIV/AIDS have access to a safe, reliable and affordable source of access to cannabis to manage a variety of symptoms," said Gary Lacasse, Executive Director, Canadian AIDS Society. "Our own research has been looking at barriers to access and suggesting ways to address them. Continued health services research will be important, as we implement a new system, to assess how well it is meeting the needs of patients."
The full text of the associations' submission is available here: The Arthritis Society / CFAMM.
About The Arthritis Society
The Arthritis Society has been setting lives in motion for over 65 years. Dedicated to a vision of living well while creating a future without arthritis, The Society is Canada's principal health charity providing education, programs and support to the over 4.6 million Canadians living with arthritis. Since its founding in 1948, The Society has been the largest non‐government funder of arthritis research in Canada, investing over $190 million in projects that have led to breakthroughs in the diagnosis, treatment and care of people with arthritis. The Arthritis Society is accredited under Imagine Canada's Standards Program. For more information and to make a donation, visit www.arthritis.ca.
About Canadians for Fair Access to Medical Marijuana
Founded in 2014, Canadians for Fair Access to Medical Marijuana (CFAMM) is a federal non-profit, patient-run organization dedicated to protecting and improving the rights of medical cannabis patients. CFAMM's goal is to enable patients to obtain fair and safe access to medical cannabis with a special focus on affordability, including private and public insurance coverage. For more information, visit www.cfamm.ca.
About the Canadian AIDS Society
Incorporated since 1986, the Canadian AIDS Society (CAS) is a national coalition of community-based AIDS organizations across Canada. CAS is dedicated to strengthening the response to HIV/AIDS across all sectors of society, and to enriching the lives of people and communities living with HIV/AIDS. For more information, please visit www.cdnaids.ca
For further information contact:
Douglas Emerson
National Manager, Communications
The Arthritis Society
W: 416.979.7228 x3348
C: 647.706.0440
[email protected]
Jonathan Zaid
Founder & Executive Director
Canadians for Fair Access to Medical Marijuana
226-444-8139
[email protected]
Dr. Lynne Belle-Isle
National Programs Manager
Canadian AIDS Society
C: 250-884-1609
[email protected]
CONTACT: For further information contact:
Douglas Emerson
National Manager, Communications
The Arthritis Society
W: 416.979.7228 x3348
C: 647.706.0440
[email protected]
Jonathan Zaid
Founder & Executive Director
Canadians for Fair Access to Medical Marijuana
226-444-8139
[email protected]
Dr. Lynne Belle-Isle
National Programs Manager
Canadian AIDS Society
C: 250-884-1609
[email protected]


Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 



